https://scholars.lib.ntu.edu.tw/handle/123456789/484029
標題: | Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials | 作者: | YU-YUN SHAO Shau, W.-Y. Chan, S.-Y. LI-CHUN LU CHIH-HUNG HSU ANN-LII CHENG |
關鍵字: | Hepatitis B virus | Hepatitis C virus | Hepatocellular carcinoma | Meta-analysis | Sorafenib;Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Meta-analysis; Sorafenib | 公開日期: | 2015 | 卷: | 88 | 期: | 6 | 來源出版物: | Oncology (Switzerland) | 摘要: | © 2015 S. Karger AG, Basel. Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any specific subgroups of patients may gain more survival benefits from sorafenib as the first-line therapy for advanced HCC. Methods: PubMed and the Cochrane library were searched for phase III clinical trials that compared sorafenib with other treatments as first-line therapy for advanced HCC. We retrieved data from the published articles and then calculated synthesized hazard ratios (HRs) of overall mortality for patients of different subgroups, using patients who received other treatments as the reference. Results: Four phase III clinical trials comparing sorafenib with other treatments were included in this study. The HRs were not significantly different between patients from various geographic regions (p = 0.183), patients with different Eastern Cooperative Oncology Group performance statuses (p = 0.699), or patients with different tumor involvement (p = 0.221). By contrast, the synthesized HR for hepatitis C virus (HCV)+ patients was 0.65 [95% confidence interval (CI) 0.53-0.80], which was significantly lower than that for HCV- patients (0.87, 95% CI 0.79-0.96, p = 0.013). Conclusions: As the first-line therapy for advanced HCC, sorafenib might provide more survival benefits to HCV+ patients than to HCV- patients. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/484029 | ISSN: | 0030-2414 1423-0232 |
DOI: | 10.1159/000369559 16897273 |
SDG/關鍵字: | brivanib; sorafenib; sunitinib; antineoplastic agent; carbanilamide derivative; nicotinamide; sorafenib; Article; Asian; cancer chemotherapy; cancer mortality; cancer patient; cancer survival; cause of death; drug efficacy; hepatitis B; hepatitis C; human; liver cell carcinoma; meta analysis; phase 3 clinical trial (topic); priority journal; randomized controlled trial (topic); systematic review; analogs and derivatives; Carcinoma, Hepatocellular; hepatitis B; hepatitis C; Liver Neoplasms; middle aged; pathology; survival; treatment outcome; virology; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。